Mi­cro­bio­me up­start Vedan­ta teams up with NYU Lan­gone sci­en­tist on check­point drugs

Aca­d­e­m­ic col­lab­o­ra­tions have been cen­tral to the de­vel­op­ment of new im­muno-on­col­o­gy drugs. And now the mi­cro­bio­me start­up Vedan­ta Bio­sciences is fol­low­ing the same sci­en­tif­ic trail …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.